TENAX THERAPEUTICS, INC. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from Q2 2013 to Q4 2022
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Tenax Therapeutics, Inc. annual/quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from Q2 2013 to Q4 2022.
- Tenax Therapeutics, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending December 31, 2022 was $2.55M.
- Tenax Therapeutics, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending December 31, 2022 was $11M.
- Tenax Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was $7.71M, a 30.2% decline from 2022.
- Tenax Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was $11M.
- Tenax Therapeutics, Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$32.5M, a 430% decline from 2020.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Growth (%)